Viking Therapeutics Inc. priced a public offering of 5,130,435 common shares at $2.50 apiece to raise $12.8 million in gross proceeds.

William Blair & Co. LLC is acting as sole book-running manager for the offering, with Maxim Group LLC and Roth Capital Partners acting as co-managers.

The offering's underwriters can buy up to an additional 769,565 of the shares offered.

The offering, which is expected to close by Dec. 11, will help raise funds for the development of the company's product pipeline.